NDC 73069-024

Viatrexx-Adipose

Epinephrine , Artery , Metenkefalin , Adenosine Triphosphate , Adenosine Cyclic Phosphate , Centella Asiatica , Citric Acid Monohydrate , Coenzyme A , Colchicum Autumnale Bulb , Fumaric Acid , Interleukin-10 , Levocarnitine , Lactic Acid , Pancrelipase Lipase , Liver , Lymph, Sodium Diethyl Oxalacetate , Sodium Pyruvate , Pituitary Gland, Quinhydrone , Succinic Acid , Parathyroid Gland, Vein, Yohimbine, Ferrous Fumarate, Mecasermin, Potassium Aspartate And Momordica Balsamina Whole

Viatrexx-Adipose is a Intramuscular; Intravenous; Parenteral; Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Viatrexx Bio Incorporated. The primary component is Epinephrine; Bos Taurus Artery; Sus Scrofa Artery; Adenosine Triphosphate; Adenosine Cyclic Phosphate; Centella Asiatica; Citric Acid Monohydrate; Coenzyme A; Colchicum Autumnale Bulb; Fumaric Acid; Interleukin-10; Levocarnitine; Lactic Acid; Pancrelipase Lipase; Beef Liver; Pork Liver; Sus Scrofa Lymph; Bos Taurus Lymph; Sodium Diethyl Oxalacetate; Sodium Pyruvate; Sus Scrofa Pituitary Gland; Bos Taurus Pituitary Gland; Quinhydrone; Succinic Acid; Bos Taurus Parathyroid Gland; Sus Scrofa Parathyroid Gland; Bos Taurus Vein; Sus Scrofa Vein; Yohimbine; Ferrous Fumarate; Mecasermin; Potassium Aspartate; Momordica Balsamina Whole.

Product ID73069-024_aa6d1c5c-dd65-40b6-bef4-d027a4a8d5e4
NDC73069-024
Product TypeHuman Prescription Drug
Proprietary NameViatrexx-Adipose
Generic NameEpinephrine , Artery , Metenkefalin , Adenosine Triphosphate , Adenosine Cyclic Phosphate , Centella Asiatica , Citric Acid Monohydrate , Coenzyme A , Colchicum Autumnale Bulb , Fumaric Acid , Interleukin-10 , Levocarnitine , Lactic Acid , Pancrelipase Lipase , Liver , Lymph, Sodium Diethyl Oxalacetate , Sodium Pyruvate , Pituitary Gland, Quinhydrone , Succinic Acid , Parathyroid Gland, Vein, Yohimbine, Ferrous Fumarate, Mecasermin, Potassium Aspartate And Momordica Balsamina Whole
Dosage FormInjection
Route of AdministrationINTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS
Marketing Start Date2019-03-29
Marketing CategoryUNAPPROVED DRUG OTHER / UNAPPROVED DRUG OTHER
Labeler NameVIATREXX BIO INCORPORATED
Substance NameEPINEPHRINE; BOS TAURUS ARTERY; SUS SCROFA ARTERY; ADENOSINE TRIPHOSPHATE; ADENOSINE CYCLIC PHOSPHATE; CENTELLA ASIATICA; CITRIC ACID MONOHYDRATE; COENZYME A; COLCHICUM AUTUMNALE BULB; FUMARIC ACID; INTERLEUKIN-10; LEVOCARNITINE; LACTIC ACID; PANCRELIPASE LIPASE; BEEF LIVER; PORK LIVER; SUS SCROFA LYMPH; BOS TAURUS LYMPH; SODIUM DIETHYL OXALACETATE; SODIUM PYRUVATE; SUS SCROFA PITUITARY GLAND; BOS TAURUS PITUITARY GLAND; QUINHYDRONE; SUCCINIC ACID; BOS TAURUS PARATHYROID GLAND; SUS SCROFA PARATHYROID GLAND; BOS TAURUS VEIN; SUS SCROFA VEIN; YOHIMBINE; FERROUS FUMARATE; MECASERMIN; POTASSIUM ASPARTATE; MOMORDICA BALSAMINA WHOLE
Active Ingredient Strength31 [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL
Pharm ClassesAdrenergic alpha-Agonists [MoA],Adrenergic beta-Agonists [MoA],alpha-Adrenergic Agonist [EPC],beta-Adrenergic Agonist [EPC],Catecholamine [EPC],Catecholamines [CS],Acidifying Activity [MoA],Calculi Dissolution Agent [EPC],Anti-coagulant [EPC],Decreased Coagulation Factor Activity [PE],Calcium Chelating Activity [MoA],Carnitine [CS],Carnitine Analog [EPC],Non-Standardized Food Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Allergens [CS],Dietary Proteins [CS],Meat Proteins [EXT]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 73069-024-76

12 VIAL, MULTI-DOSE in 1 BOX (73069-024-76) > 50 mL in 1 VIAL, MULTI-DOSE
Marketing Start Date2019-05-06
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 73069-024-49 [73069002449]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-54 [73069002454]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-42 [73069002442]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-05

NDC 73069-024-39 [73069002439]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-72 [73069002472]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-18 [73069002418]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-33 [73069002433]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-15 [73069002415]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-55 [73069002455]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-88 [73069002488]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-85 [73069002485]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-27 [73069002427]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-24 [73069002424]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-78 [73069002478]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-22 [73069002422]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-21 [73069002421]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-76 [73069002476]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-11 [73069002411]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-71 [73069002471]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-29 [73069002429]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-16 [73069002416]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-62 [73069002462]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-14 [73069002414]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-23 [73069002423]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-89 [73069002489]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-13 [73069002413]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-19 [73069002419]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-26 [73069002426]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-82 [73069002482]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-12 [73069002412]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-41 [73069002441]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-05

NDC 73069-024-69 [73069002469]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-43 [73069002443]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-47 [73069002447]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-58 [73069002458]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-31 [73069002431]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-87 [73069002487]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-68 [73069002468]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-74 [73069002474]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-79 [73069002479]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-67 [73069002467]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-51 [73069002451]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-75 [73069002475]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-57 [73069002457]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-63 [73069002463]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-53 [73069002453]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-64 [73069002464]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-37 [73069002437]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-35 [73069002435]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-36 [73069002436]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-56 [73069002456]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-46 [73069002446]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-05

NDC 73069-024-32 [73069002432]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-48 [73069002448]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-81 [73069002481]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-66 [73069002466]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-65 [73069002465]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-44 [73069002444]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-05

NDC 73069-024-34 [73069002434]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-28 [73069002428]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-52 [73069002452]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-59 [73069002459]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-83 [73069002483]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-61 [73069002461]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-77 [73069002477]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-45 [73069002445]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-73 [73069002473]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-86 [73069002486]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-84 [73069002484]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-38 [73069002438]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-17 [73069002417]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

NDC 73069-024-25 [73069002425]

Viatrexx-Adipose INJECTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-06

Drug Details

Active Ingredients

IngredientStrength
EPINEPHRINE31 [kp_C]/mL

OpenFDA Data

SPL SET ID:65c43495-a474-4182-8738-79ffb1663c63
Manufacturer
UNII
UPC Code
  • 0073069024416
  • 0073069024423
  • Pharmacological Class

    • Adrenergic alpha-Agonists [MoA]
    • Adrenergic beta-Agonists [MoA]
    • alpha-Adrenergic Agonist [EPC]
    • beta-Adrenergic Agonist [EPC]
    • Catecholamine [EPC]
    • Catecholamines [CS]
    • Acidifying Activity [MoA]
    • Calculi Dissolution Agent [EPC]
    • Anti-coagulant [EPC]
    • Decreased Coagulation Factor Activity [PE]
    • Calcium Chelating Activity [MoA]
    • Carnitine [CS]
    • Carnitine Analog [EPC]
    • Non-Standardized Food Allergenic Extract [EPC]
    • Increased Histamine Release [PE]
    • Cell-mediated Immunity [PE]
    • Allergens [CS]
    • Dietary Proteins [CS]
    • Meat Proteins [EXT]
    • Adrenergic alpha-Agonists [MoA]
    • Adrenergic beta-Agonists [MoA]
    • alpha-Adrenergic Agonist [EPC]
    • beta-Adrenergic Agonist [EPC]
    • Catecholamine [EPC]
    • Catecholamines [CS]
    • Acidifying Activity [MoA]
    • Calculi Dissolution Agent [EPC]
    • Anti-coagulant [EPC]
    • Decreased Coagulation Factor Activity [PE]
    • Calcium Chelating Activity [MoA]
    • Carnitine [CS]
    • Carnitine Analog [EPC]
    • Non-Standardized Food Allergenic Extract [EPC]
    • Increased Histamine Release [PE]
    • Cell-mediated Immunity [PE]
    • Allergens [CS]
    • Dietary Proteins [CS]
    • Meat Proteins [EXT]

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.